The majority of the BC patients were at clinical cancer stage T0–T2 (74%) and were predominantly estrogen receptor (ER) positive (66%), progesterone receptor (PR) positive (59%), and ductal carcinoma (94%) with a well differentiated/moderately differentiated (G1/G2) tumor histological grade (68%) (Table 1). This evidence concerns the gene ESR1 and breast cancer.